Friday 20th May 2016
|Text too small?|
A2 Milk Co brushed off a 'please explain' notice from the stock market operator after its shares plunged to a five-month low saying it complied with listing rules, while separately, brokerage firm First NZ Capital noted uncertainty creeping into the market as four new entrants start selling milk with the A2-type protein.
The Auckland-based, Sydney-headquartered company said it continued to comply with continuous disclosure rules after NZX queried a 22 percent slump in the share price since May 17, which saw the shares fall as low as $1.40, the lowest since Dec. 18. The shares were recently at $1.59, down 1.2 percent today and 11 percent this week.
The query comes as First NZ Capital sent out a note to clients that the strength of A2's patents is set to be tested with a number of unrelated firms either launching or preparing to launch milk products with the A2 variant protein.
"From our perspective, albeit these parties appear to be small scale operators, the breadth and depth of ATM's registered patents may be about to be put through significant tests," the report said. "Conversely, it (could) also be seen as an endorsement of the potential benefits that the A2-type milk could bring to some dairy consumer beyond the lone voice of ATM (A2 Milk) in the market to date."
First NZ notes Ohio,US-based Snowville Creamery, Origin Milk, and Hidden Acre Farms all separately make claims around the benefits of A2 proteins, referencing A2 on its packaging, while Netherlands-based Veco Zuivel has been reported as planning to make A2-type products available later this year.
"We note all of these four companies have made statements relating to the potential benefits of A2 type milk on their websites or in media releases, but did not make any reference to 'The a2 Milk Company' or the 'a2' brand," First NZ said. "None of these four contacted ATM prior (to) launching their products in the market."
A2 Milk has been trying to get more credible scientific validation of its marketing claims since the 1990s, and last month heralded a Chinese study published in the Nutrition Journal that found milk containing the A1 beta-casein worsened gastrointestinal symptoms and slowed cognitive processing speed whereas the milk with A2 beta-casein had no adverse effect. Further clinical trials are underway in China and Auckland.
First NZ kept its target price unchanged at $1.67, with its view based on whether the company can successfully execute its plan to sell A2-variety milk products in Australia, the UK, and US, and crack the Chinese and Australian infant formula markets.
No comments yet
Stocks Tumble, Havens Gain on Rising Virus Concern
25th February 2020 Morning Report
NZ dollar stalled amid ongoing coronavirus concern
Member growth delivers healthy results for nib New Zealand
The Australian Dollar Nears a Tipping Point Thanks to Ultra-Low Rates
With Gold Surging, Miners Face Payouts Versus Production Dilemma
24th February 2020 Morning Report
U.S. Dollar Nears a Critical Level That May Trigger a Buying Spree
21st February 2020 Morning Report
Tech Leads Stocks Lower on Virus Fears; Gold Gains